Subcutaneous Nitroglycerin to Facilitate Trans-radial Access.
Key facts
- Who runs it
- Instituto Nacional de Cardiologia Ignacio Chavez
- Where
- Mexico1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Suspended
- Phase
- Phase 4
- People taking part
- 1,400 people, planned
- Started
- 30 Mar 2018
- Ended
- 31 Mar 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Nitroglycerin 100 MCG/ML Injectable Solution
- Saline Solution
- Record updated
- 18 March 2026
- Why it stopped
- The sample was not completed.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Men and women older than 18 years, scheduled consecutively to perform a coronary procedure in the department of hemodynamics of the National Institute of Cardiology "Ignacio Chavez"
- Patients may have any of the following indications for cardiac catheterization: Thoracic pain under study. Stable chronic coronary disease. Acute myocardial infarction with ST segment elevation, not perfused (without timely reperfusion therapy) with less than 4 weeks of evolution. Acute myocardial infarction with ST-segment elevation, successful thrombolytic therapy, which will undergo drug-invasive therapy. Acute myocardial infarction without ST segment elevation. Unstable angina. Any acute coronary syndrome, to intervene non-infarct-related artery. Disease of any heart valve. Myocarditis or pericarditis. Dilated cardiomyopathy. Patients in renal or cardiac transplantation protocol for any etiology. Congenital heart disease that requires knowing the coronary anatomy prior to surgical correction
- The planned procedure can be any of the following: For diagnostic purposes (coronary angiography only, left catheterization, left and right catheterization). For therapeutic purposes: percutaneous coronary intervention (PCI), with or without stent placement
- A priori access must be right or left radial artery
- Radial arterial pulse may be present or absent by palpation
- Modified Allen or Barbeau test should be positive (presence of collateral palmar flow)
Who cannot take part
- Any phosphodiesterase 5 inhibitor (sildenafil, tadalafil, avanafil, vardenafil) has been taken within 72 hours prior to the study
- With acute myocardial infarction with ST segment elevation in the first 12 hours from the onset of symptoms
- With any acute coronary syndrome complicated with acute pulmonary edema, cardiogenic shock and / or malignant ventricular arrhythmias
- In which a cardiac catheterization is planned a priori to be performed via femoral, brachial or ulnar
- Be allergic or have contraindications to nitroglycerin or other nitrates
- Pregnant
- Not have informed consent for the present clinical trial, or do not fully understand the meaning of informed consent
- Patients in whom first attempt of arterial puncture is performed by 2nd year interventional cardiology fellow or by physician in charge
- Participating in another clinical trial
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Femoral artery approach to perform coronary procedures is considered the standard technique for vascular access due to optimal catheter control, lower thromboembolic complications and immediate access due to the large diameter of the artery. Trans-radial approach has been shown to reduce major bleeding complications, vascular complications related to the site of puncture, including death from all causes, and to prevent post-procedure limb rest, greater comfort for patients, immediate ambulation, early discharge and reduction of costs. Previous studies have shown that intravenous, topical and intraarterial use of nitroglycerin produces vasodilation of the radial artery. Extravascular (subcutaneous) administration of nitroglycerin is extremely effective in restoring the radial pulse, and allows adequate cannulation.
The 2 groups in the trial
- NitroglycerinTreatment being tested
The intervention group will receive a subcutaneous "cocktail" with 0,5 ml of 500 mcg of nitroglycerin + 1 ml of 2% simple lidocaine.
Treatment: Nitroglycerin 100 MCG/ML Injectable Solution
- ControlPlacebo, for comparison
The placebo group will receive a subcutaneous injection with 0,5 ml of 0,9% saline solution + 1 ml of 2% simple lidocaine.
Treatment: Saline Solution
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Subcutaneous Administration of Nitroglycerin to Facilitate Trans-radial Access in Coronary Procedures: a Randomized Clinical Trial (NITRAD-Sub Study).
- Record updated
- 18 March 2026